A phase I study of oxaliplatin in combination with gemcitabine: Correlation of clinical outcome with gene expression

Cancer Chemotherapy and Pharmacology

Volumn 59, Issue 4, 2007, Pages 549-557

  Shibata, Stephen ^a   Chow, Warren ^a   Frankel, Paul ^a   Juhasz, Agnes ^a   Leong, Lucille ^a   Lim, Dean ^a   Margolin, Kim ^a   Morgan, Robert ^a   Newman, Edward ^a   Somlo, George ^a   Yen, Yun ^a   Synold, Timothy ^a   Gandara, David ^b   Lenz, Heinz Josef ^c   Doroshow, James ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Gemcitabine; Oxaliplatin; Pharmacokinetics; Ribonucleotide reductase

Indexed keywords

GEMCITABINE; OXALIPLATIN; RIBONUCLEOTIDE REDUCTASE;

ADULT; AGED; AMNESIA; ARTICLE; BIOCHEMISTRY; BLOOD TOXICITY; BLURRED VISION; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CANCER; CONFUSION; CORRELATION ANALYSIS; DIARRHEA; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; OUTCOME ASSESSMENT; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOLID TUMOR; THROMBOCYTOPENIA; TUMOR BIOPSY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; ORGANOPLATINUM COMPOUNDS; RIBONUCLEOSIDE DIPHOSPHATE REDUCTASE; RNA, MESSENGER;

EID: 33846326914     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-006-0297-3     Document Type: Article

References (55)

1. Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B, Mineishi S, Tarassoff P, Satterlee W, Raber MN et al (1991) A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 9:491-498
2. Aebi S, Kurdi-Haidar B, Gordon R, Cenni B, Zheng H, Fink D, Christen RD, Boland CR, Koi M, Fishel R, Howell SB (1996) Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 56:3087-3090
3. Alberts SR, Townley PM, Goldberg RM, Cha SS, Moore DF Jr, Krook JE, Pitot HC, Fitch TR, Wiesenfeld M, Mailliard JA, Sargent DJ (2002) Gemcitabine and oxaliplatin for patients with advanced or metastatic pancreatic cancer: a North Central Cancer Treatment Group (NCCTG) phase I study. Ann Oncol 13:553-557
4. Alberts SR, Townley PM, Goldberg RM, Cha SS, Sargent DJ, Moore DF, Krook JE, Pitot HC, Fitch TR, Wiesenfeld M, Mailliard JA (2003) Gemcitabine and oxaliplatin for metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II study. Ann Oncol 14:580-585
5. Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de Gramont A (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343-2351
6. Andre T, Tournigand C, Rosmorduc O, Provent S, Maindrault-Goebel F, Avenin D, Selle F, Paye F, Hannoun L, Houry S, Gayet B, Lotz JP, de Gramont A, Louvet C (2004) Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol 15:1339-1343
7. Bepler G, Sharma S, Cantor A, Gautam A, Haura E, Simon G, Sharma A, Sommers E, Robinson L (2004) RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer. J Clin Oncol 22:1878-1885
8. Bergman AM, Ruiz v HV, Veerman G, Kuiper CM, Peters GJ (1996) Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res 2:521-530
9. Bidoli P, Stani SC, Mariani L, De Candis D, Cortinovis D, Aglione S, Zilembo N, Toffolatti L, Formisano B, Bajetta E (2004) Phase I study of escalating doses of oxaliplatin in combination with fixed dose gemcitabine in patients with non-small cell lung cancer. Lung Cancer 43:203-208
10. Cassidy J, Misset JL (2002) Oxaliplatin-related side effects: characteristics and management. Semin Oncol (Suppl 15) 29:11-20
11. Chollet P, Bensmaine MA, Brienza S, Deloche C, Cure H, Caillet H, Cvitkovic E (1996) Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer. Ann Oncol 7:1065-1070
12. Colucci G, Giuliani F, Gebbia V, Biglietto M, Rabitti P, Uomo G, Cigolari S, Testa A, Maiello E, Lopez M (2002) Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale. Cancer 94:902-910
13. Doroshow J, Tetef M, Margolin K, Somlo G, Frankel P, Longmate J, Synold T, Gandara D, Lenz HJ, Albain K (2000) Significant activity of gemcitabine and cisplatin in both heavily and minimally-pretreated metastatic breast cancer patients: a California Cancer Consortium/Loyola University Chicago Trial Proc ASCO 19:155a
14. Doroshow JH, Synold TW, Gandara D, Mani S, Remick SC, Mulkerin D, Hamilton A, Sharma S, Ramanathan RK, Lenz HJ, Graham M, Longmate J, Takimoto CH, Ivy P (2003) Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: a preliminary report of the National Cancer Institute Organ Dysfunction Working Group. Semin Oncol Aug (Suppl 15) 30:14-19
15. Duenas-Gonzalez A, Lopez-Graniel C, Gonzalez A, Gomez E, Rivera L, Mohar A, Chanona G, Trejo-Becerril C, de la GJ (2003) Induction chemotherapy with gemcitabine and oxaliplatin for locally advanced cervical carcinoma. Am J Clin Oncol 26:22-25
16. Ellis RE (1961) The distribution of active bone marrow in the adult. Phys Med Biol 5:255-258
17. Faivre S, Kalla S, Cvitkovic E, Bourdon O, Hauteville D, Dourte LM, Bensmaine M A, Itzhaki M, Marty M, Extra JM (1999) Oxaliplatin and paclitaxel combination in patients with platinum-pretreated ovarian carcinoma: an investigator-originated compassionate-use experience. Ann Oncol 10:1125-1128
18. Faivre S, Le Chevalier T, Monnerat C, Lokiec F, Novello S, Taieb J, Pautier P, Lhomme C, Ruffie P, Kayitalire L, Armand JP, Raymond E (2002) Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma. Ann Oncol 13:1479-1489
19. Faivre S, Raymond E, Woynarowski JM, Cvitkovic E (1999) Supraadditive effect of 2′,2′-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines. Cancer Chemother Pharmacol 44:117-123
20. Fink D, Nebel S, Aebi S, Zheng H, Cenni B, Nehme A, Christen RD, Howell SB (1996) The role of DNA mismatch repair in platinum drug resistance. Cancer Res 56:4881-4886
21. Fink D, Zheng H, Nebel S, Norris PS, Aebi S, Lin TP, Nehme A, Christen RD, Haas M, MacLeod CL, Howell SB (1997) In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res 57:1841-1845
22. Franciosi V, Barbieri R, Aitini E, Vasini G, Cacciani GC, Capra R, Camisa R, Cascinu S (2003) Gemcitabine and oxaliplatin: a safe and active regimen in poor prognosis advanced non-small cell lung cancer patients. Lung Cancer 41:101-106
23. Freeman KB, Anliker S, Hamilton M, Osborne D, Dhahir PH, Nelson R, Allerheiligen SR (1995) Validated assays for the determination of gemcitabine in human plasma and urine using high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Appl 665:171-181
24. Garufi C, Nistico C, Brienza S, Vaccaro A, D'Ottavio A, Zappala AR, Aschelter AM, Terzoli E (2001) Single-agent oxaliplatin in pretreated advanced breast cancer patients: a phase II study. Ann Oncol 12:179-182
25. Goan YG, Zhou B, Hu E, Mi S, Yen Y (1999) Overexpression of ribonucleotide reductase as a mechanism of resistance to 2, 2- difluorodeoxycytidine in the human KB cancer cell line. Cancer Res 59:4204-4207
26. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts SR (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23-30
27. Graham MA, Lockwood GF, Greenslade D, Brienza S, Bayssas M, Gamelin E, (2000) Clinical pharmacokinetics of oxaliplatin: a critical review. Clin Cancer Res 6:1205-1218
28. Juhasz A, Frankel P, Cheng C, Rivera H, Vishwanath R, Chiu A, Margolin K, Yen Y, Newman EM, Synold T, Wilczynski S, Lenz HJ, Gandara D, Albain KS, Longmate J, Doroshow JH (2003) Quantification of chemotherapeutic target gene mRNA expression in human breast cancer biopsies: comparison of real-time reverse transcription-PCR vs. relative quantification reverse transcription-PCR utilizing DNA sequencer analysis of PCR products. J Clin Lab Anal 17:184-194
29. Kidani Y, Noji M, Tashiro T (1980) Antitumor activity of platinum(II) complexes of 1,2-diamino-cyclohexane isomers. Gann 71:637-643
30. Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, Andre T, Zaniboni A, Ducreux M, Aitini E, Taieb J, Faroux R, Lepere C, de Gramont A (2005) Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 23:3509-3516
31. Mamenta EL, Poma EE, Kaufmann WK, Delmastro DA, Grady HL, Chaney SG (1994) Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res 54:3500-3505
32. Mavroudis D, Pappas P, Kouroussis C, Kakolyris S, Agelaki S, Kalbakis K, Androulakis N, Souglakos J, Vardakis N, Nikolaidou M, Samonis G, Marselos M, Georgoulias V (2003) A dose-escalation and pharmacokinetic study of gemcitabine and oxaliplatin in patients with advanced solid tumors. Ann Oncol 14:304-312
33. Monnet I, Brienza S, Hugret F, Voisin S, Gastiaburu J, Saltiel JC, Soulie P, Armand JP, Cvitkovic E, de Cremoux H (1998) Phase II study of oxaliplatin in poor-prognosis non-small cell lung cancer (NSCLC) ATTIT Association pour le Traitement des Tumeurs Intra Thoraciques. Eur J Cancer 34:1124-1127
34. Pavlakis N, Bell DR, Millward MJ, Levi JA (1997) Fatal pulmonary toxicity resulting from treatment with gemcitabine. Cancer 80:286-291
35. Pectasides D, Pectasides M, Farmakis D, Aravantinos G, Nikolaou M, Koumpou M, Gaglia A, Kostopoulou V, Mylonakis N, Skarlos D (2004) Gemcitabine and oxaliplatin (GEMOX) in patients with cisplatin-refractory germ cell tumors: a phase II study. Ann Oncol 15:493-497
36. Pendyala L, Kidani Y, Perez R, Wilkes J, Bernacki RJ, Creaven PJ (1995) Cytotoxicity, cellular accumulation and DNA binding of oxaliplatin isomers. Cancer Lett. 97:177-184
37. Plunkett W, Huang P, Searcy CE, Gandhi V (1996) Gemcitabine: preclinical pharmacology and mechanisms of action. Semin. Oncol (Suppl 10) 23:3-15
38. Porta C, Zimatore M, Imarisio I, Natalizi A, Sartore-Bianchi A, Danova M, Riccardi A (2004) Gemcitabine and oxaliplatin in the treatment of patients with immunotherapy-resistant advanced renal cell carcinoma: final results of a single-institution Phase II study. Cancer 100:2132-2138
39. Poplin E, Levy E, Berlin M, Rothenberg M, Cella D, Mitchell E, Alberts S, and Benson III A. A phase III trial of gemcitabine (30-min infusion) versus gemcitabine (fixed-dose-rate infusion [FDR]) versus gemcitabine + oxaliplatin (GEMOX) in patients with advanced pancreatic cancer. Proc ASCO 24, No 18s aLBA4004
40. Raspagliesi F, Zanaboni F, Vecchione F, Hanozet F, Scollo P, Ditto A, Grijuela B, Fontanelli R, Solima E, Spatti G, Scibilia G, Kusamura S (2004) Gemcitabine combined with oxaliplatin (GEMOX) as second-line chemotherapy in patients with advanced ovarian cancer refractory or resistant to platinum and taxane. Oncology 67:376-381
41. Raymond E, Faivre S, Woynarowski JM, Chaney SG (1998) Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol (Suppl 5) 25:4-12
42. Rixe O, Ortuzar W, Alvarez M, Parker R, Reed E, Paull K, Fojo T (1996) Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem.Pharmacol 52:1855-1865
43. Rosell R, Danenberg KD, Alberola V, Bepler G, Sanchez JJ, Camps C, Provencio M, Isla D, Taron M, Diz P, Artal A (2004) Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 10:1318-1325
44. Rothenberg ML, Oza AM, Bigelow RH, Berlin JD, Marshall JL, Ramanathan RK, Hart LL, Gupta S, Garay CA, Burger BG, Le Bail N, Haller DG (2003) Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 21:2059-2069
45. Sandler AB, Nemunaitis J, Denham C, von Pawel J, Cormier Y, Gatzemeier U, Mattson K, Manegold C, Palmer MC, Gregor A, Nguyen B, Niyikiza C, Einhorn LH (2000) Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 18:122-130
46. Schmidt W, Chaney SG (1993) Role of carrier ligand in platinum resistance of human carcinoma cell lines. Cancer Res 53:799-805
47. Schutte W, Blankenburg T, Lauerwald K, Schreiber J, Bork I, Wollscgkaeger B, Treutler D, Schneider CP, Bonner R (2003) A multicenter phase II study of gemcitabine and oxaliplatin for malignant pleural mesothelioma. Clin Lung Cancer 4:294-297
48. Soulie P, Bensmaine A, Garrino C, Chollet P, Brain E, Fereres M, Jasmin C, Musset M, Misset JL, Cvitkovic E (1997) Oxaliplatin/cisplatin (L-OHP/CDDP) combination in heavily pretreated ovarian cancer. Eur J Cancer 33:1400-1406
49. Takimoto CH, Remick SC, Sharma S, Mani S, Ramanathan RK, Doroshow J, Hamilton A, Mulkerin D, Graham M, Lockwood GF, Ivy P, Egorin M, Schuler B, Greenslade D, Goetz A, Knight R, Thomas R, Monahan BP, Dahut W, Grem JL (2003) Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study. J Clin Oncol 21:2664-2672
50. Vaisman A, Varchenko M, Umar A, Kunkel TA, Risinger JI, Barrett JC, Hamilton TC, Chaney SG (1998) The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts. Cancer Res 58:3579-3585
51. van Moorsel CJ, Pinedo HM, Veerman G, Bergman AM, Kuiper CM, Vermorken JB, van der Vijgh WJ, Peters GJ (1999) Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines. Br J Cancer 80:981-990
52. Venook AP, Egorin MJ, Rosner GL, Hollis D, Mani S, Hawkins M, Byrd J, Hohl R, Budman D, Meropol NJ, Ratain MJ (2000) Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565. J Clin Oncol 18:2780-2787
53. von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A, Lippert CM, Kerbrat P, Sanchez RP, Wersall P, Cleall SP, Roychowdhury DF, Tomlin I, Visseren-Grul CM, Conte PF (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18:3068-3077
54. Woynarowski JM, Chapman WG, Napier C, Herzig MC, Juniewicz P (1998) Sequence- and region- specificity of oxaliplatin adducts in naked and cellular DNA. Mol Pharmacol 54:770-777
55. Zhou BS, Ker R, Ho R, Yu J, Zhao YR, Shih J, Yen Y (1998) Determination of deoxyribonucleoside triphosphate pool sizes in ribonucleotide reductase cDNA transfected human KB cells. Biochem.Pharmacol 55:1657-1665